Preliminary evidence suggests that GLP-1 RAs, such as exendin-4, can enhance the effectiveness of chemotherapies like gemcitabine in pancreatic cancer, reducing tumour burden more than either treatment alone through complementary antiproliferative and pro-death mechanisms [16]. This evidence concerns the gene GLP1R and pancreatic neoplasm.